PDF herunterladen
Arzneimittelforschung 2008; 58(5): 211-214
DOI: 10.1055/s-0031-1296496
Cardiac Drugs · Cardiac Stimulants · Coronary Drugs
Editio Cantor Verlag Aulendorf (Germany)

Bio equivalence of Two Formulations of Daidzein Administered in a Single Dose to Healthy Chinese Volunteers

Jianchang He
1   Kunming General Hospital of Chengdu Military Command, Kunming, P. R. China
,
Shenghua Gu
2   Key Laboratory of Drug Metabolism and Pharmacokinetic, China Pharmaceutical University, Nanjing, P. R. China
,
Qing Zhang
1   Kunming General Hospital of Chengdu Military Command, Kunming, P. R. China
,
Enfu Feng
1   Kunming General Hospital of Chengdu Military Command, Kunming, P. R. China
,
Xingyi Li
1   Kunming General Hospital of Chengdu Military Command, Kunming, P. R. China
,
Guili Xu
1   Kunming General Hospital of Chengdu Military Command, Kunming, P. R. China
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
15. Dezember 2011 (online)

    Lizenzen und Reprints

Abstract

In this two-treatment, two-period, randomized, crossover bioequivalence study of daidzein, which belongs to the isoflavone class of flavonoids and is classified as a phytoestrogen, two formulations (dripping pills, a rapidly-dissolvable formulation, and tablets) were compared in 20 healthy Chinese male subjects. The drug was given in a single dose of 50 mg and blood samples were withdrawn during 24 h after drug administration. Daidzein was separated and analyzed using a validated liquid chromatography – tandem mass spectrometry (LC-MS/MS) method. The pharmacokinetic parameters were determined from the plasma concentration-time profiles of both formulations. The primary calculated pharmacokinetic parameters were compared statistically to evaluate bioequivalence between the two preparations, using various statistical methods. The analysis of variance (ANOVA) did not show any significant difference between the two formulations and 90% confidence intervals fell within the acceptable range (80 – 120%) for bioequivalence. Based on these statistical inferences it can be concluded that the two formulations of daidzein are likely to be bioequivalent.

Key words

Daidzein, bioequivalence, pharmacokinetics - Heart therapeutics - Isoflavones
 

  • References

  • 1 Li M, Poon P, Woo J. A pilot study of phytoestrogen content of soy foods and traditional Chinese medicines for women’s health in Hong Kong. Int J Food Sci Nutr. 2004; 55: 201-205
    CrossrefPubMedGoogle Scholar
  • 2 Messina MJ, Persky V, Setchell KD, Barnes S. Soy intake and cancer risk: a review of the in vitro and in vivo data. Nutr Cancer. 1994; 21: 113-131
    CrossrefPubMedGoogle Scholar
  • 3 Zhang Y, Song TT, Cunnick JE, Murphy PA, Hendrich S. Daidzein and genistein glucuronides in vitro are weakly estrogenic and activate human natural killer cells at nutritionally relevant concentrations. J Nutr. 1999; 129: 399-405
    PubMedGoogle Scholar
  • 4 Anupongsanugool E, Teekachunhatean S, Rojanasthien N, Pongsatha S, Sangdee C. Pharmacokinetics of isoflavones, daidzein and genistein, after ingestion of soy beverage compared with soy extract capsules in postmenopausal Thai women. BMC Clin Pharmacol. 2005; 5: 2-10
    PubMedGoogle Scholar
  • 5 Setchell KD, Brown NM, Desai PB, Zimmer-Nechimias L, Wolfe B, Jakate AS et al. Bioavailability, disposition, and dose-response effects of soy isoflavones when consumed by healthy women at physiologically typical dietary intakes. J Nutr. 2003; 133: 1027-1035
    PubMedGoogle Scholar